BioMarin Q1 revenue $596.4M (+15% YoY); VOXZOGO guidance raised to $380-$430M

BIOMARIN PHARMACEUTICAL INC

2023-Q1 EPS reported $0.27 revenue$596,415,000

GAAP diluted EPS $0.27 (down from $0.63 due to $89M prior-year PRV gain); Non-GAAP EPS $0.60 (up from $0.52).
VOXZOGO Q1 revenue $87.8M (+346% YoY); full-year guidance raised from $330-$380M to $380-$430M, driven by Japan and Brazil.
ROCTAVIAN full-year revenue guidance lowered to $50-$150M (from $100-$200M) due to Germany reimbursement shift and U.S. PDUFA delay to June 30, 2023.
Enzyme product revenues $448.1M (+5% YoY); ALDURAZYME up 41% on timing of orders to Sanofi.
Total cash & investments $1,492.7M; full-year revenue guidance unchanged at $2.375-$2.5B, with GAAP net income $155-$205M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOMARIN PHARMACEUTICAL INC updated its first quarter ended March 31, 2023 guidance (raised).

Period: first quarter ended March 31, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On April 26, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-23-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.